Lynn Seely

Lynn Seely is President & Chief Executive Officer at Lyell Immunopharma, Inc. since 2026.
Former roles include Chief Executive Officer at Myovant Sciences, Inc. from 2019 to 2020; President, Chief Executive Officer & Director at Myovant Sciences Ltd. from 2016 to 2021; Associate Director-Clinical Development at Chiron Corp.
from 1996 to 2000; Lead Independent Director at Blueprint Medicines Corp.
from 2016 to 2025; Director at Roivant Sciences GmbH; Chief Medical Officer at Orion Acquisition Corp.
II in 2005; Vice President-Clinical Development at Anesiva, Inc. from 2002 to 2005; Vice President-Clinical Development at Pro-Duct Health, Inc. from 2000 to 2001; Faculty Member at the University of California San Diego from 1992 to 1996; Chief Medical Officer & Senior Vice President at Medivation LLC (California) from 2009 to 2015; Vice President-Clinical Development at Cytyc Health Corp.
from 2001 to 2002; Vice President-Clinical Development at Corgentech, Inc. in 2005; Chief Resident-Internal Medicine at Yale School of Medicine.
Education includes an undergraduate degree from the University of Oklahoma in 1981 and a doctorate from the University of Oklahoma College of Medicine in 1985.